Nitrofurantoin

产品说明书

Print
Chemical Structure| 67-20-9 同义名 : NSC 2107;Macrodantin;Nitrofurantoin, Macrobid, Macrodantin, 5-Nitrofurantoin, Furadantine, Furadonine;NSC 44150;Furadonine;Furadantine
CAS号 : 67-20-9
货号 : A109585
分子式 : C8H6N4O5
纯度 : 98+%
分子量 : 238.157
MDL号 : MFCD00003224
存储条件:

Pure form Keep in dark place,Inert atmosphere,Room temperature

In solvent -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(440.89 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Nitrofurantoin is an old antibiotic and an important first-line oral antibiotic for the treatment of uncomplicated urinary tract infections. Nitrofurantoin is not a uniform product -crystal sizes of nitrofurantoin, and therefore pharmacokinetic properties, differ significantly by product[3]. A broad spectrum of liver toxicity associated with nitrofurantoin use has been reported, ranging from acute hepatitis, granulomatous reaction, cholestasis, or autoimmune-mediated hepatitis to chronic active hepatitis that could lead to cirrhosis or death[4]. On the basis of urinary nitrofurantoin excretion determined after oral and intravenous drug administration, orally administered nitrofurantoin in a suitable dosage form is well absorbed[5].
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT03466502 Clostridium Difficile Infectio... 展开 >>n 收起 << Phase 4 Enrolling by invitation March 2019 United States, Nevada ... 展开 >> Renown Regional Medical Center Reno, Nevada, United States, 89502 收起 <<
NCT01349738 - Unknown May 2013 United States, California ... 展开 >> Scripps Green Hospital La Jolla, California, United States, 92037 收起 <<
NCT03508921 Overactive Bladder ... 展开 >> Urinary Tract Infections 收起 << Phase 4 Recruiting September 1, 2019 United States, Tennessee ... 展开 >> Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

4.20mL

0.84mL

0.42mL

20.99mL

4.20mL

2.10mL

41.99mL

8.40mL

4.20mL

参考文献

[1]Yeo SJ, Jin C, et al. In Vitro and in Vivo Effects of Nitrofurantoin on Experimental Toxoplasmosis. Korean J Parasitol. 2016 Apr;54(2):155-61.

[2]Martin WJ 2nd. Nitrofurantoin: evidence for the oxidant injury of lung parenchymal cells. Am Rev Respir Dis. 1983 Apr;127(4):482-6.

[3]Wijma RA, Fransen F, Muller AE, Mouton JW. Optimizing dosing of nitrofurantoin from a PK/PD point of view: What do we need to know? Drug Resist Updat. 2019 Mar;43:1-9. doi: 10.1016/j.drup.2019.03.001. Epub 2019 Mar 20. PMID: 30947111.

[4]Sakaan SA, Twilla JD, Usery JB, Winton JC, Self TH. Nitrofurantoin-induced hepatotoxicity: a rare yet serious complication. South Med J. 2014 Feb;107(2):107-13. doi: 10.1097/SMJ.0000000000000059. PMID: 24926677.

[5]Conklin JD. The pharmacokinetics of nitrofurantoin and its related bioavailability. Antibiot Chemother (1971). 1978;25:233-52. doi: 10.1159/000401065. PMID: 352255.